Literature DB >> 12039890

Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999.

Manuel Cuenca-Estrella1, Laura Rodero, Guillermo García-Effrón, Juan L Rodriguez-Tudela.   

Abstract

The aim of this study was to identify retrospectively trends in species distribution and susceptibility patterns of Candida species causing bloodstream infections in 99 medical centres (55 in Spain and 44 in Argentina) from 1996 to 1999. A total of 744 Candida isolates were sent to the mycology reference laboratories during the study period (514 to the Spanish laboratory and 230 to the Argentinian laboratory). Candida non-albicans strains caused more episodes of fungaemia than Candida albicans isolates in both Spain and Argentina. C. albicans was isolated in 30.2% (155/514) and 40.9% (94/230) of episodes in Spain and in Argentina, respectively. In addition, Candida parapsilosis was the second most commonly isolated pathogen (36.4%). Candida tropicalis caused 13.7% of infections and Candida glabrata 7.4%. The amphotericin B MIC was <or=1 mg/L for 97.5% of isolates, and 8.3% of strains had decreased susceptibility to flucytosine. Regarding susceptibility to azole agents, 9.9% (74/744) and 21.9% (163/744) exhibited decreased susceptibility to fluconazole and itraconazole, respectively. For Candida species, some marked differences were found between countries, and decreased susceptibility to azole agents was detected significantly more frequently (P < 0.05) among Argentinian isolates of C. albicans, C. parapsilosis and C. tropicalis. These findings reinforced the need for continued surveillance programmes to analyse the factors that may have an influence on candidaemia incidence. Susceptibility patterns were obtained by means of the proposed reference procedure for antifungal susceptibility testing of the European Committee on Antibiotic Susceptibility Testing (EUCAST). Excellent interlaboratory agreement was achieved for MICs for quality control strains noted in Spain and in Argentina (intraclass correlation coefficient of 0.97), indicating that the EUCAST procedure is a reliable methodology for susceptibility testing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039890     DOI: 10.1093/jac/dkf060

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

Review 1.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 2.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain.

Authors:  J Pemán; E Cantón; M Gobernado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

4.  Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; L Boyken; S A Messer; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.

Authors:  M A Pfaller; D J Diekema; M Mendez; C Kibbler; P Erzsebet; S-C Chang; D L Gibbs; V A Newell
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

6.  Epidemiology and microbiology of nosocomial pediatric candidemia at a northern Indian tertiary care hospital.

Authors:  Avijit Kumar Awasthi; Amita Jain; Shally Awasthi; Ankur Ambast; Kamlesh Singh; Vijendra Mishra
Journal:  Mycopathologia       Date:  2011-05-01       Impact factor: 2.574

7.  In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.

Authors:  Sheng-Yuan Ruan; Chen-Chen Chu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

8.  Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection.

Authors:  S Takakura; N Fujihara; T Saito; T Kudo; Y Iinuma; S Ichiyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

9.  Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates.

Authors:  Shawn R Lockhart; Shawn A Messer; Michael A Pfaller; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2008-11-26       Impact factor: 5.948

10.  One year prospective survey of Candida bloodstream infections in Scotland.

Authors:  Frank C Odds; Mary F Hanson; Amanda D Davidson; Mette D Jacobsen; Pauline Wright; Julie A Whyte; Neil A R Gow; Brian L Jones
Journal:  J Med Microbiol       Date:  2007-08       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.